IBRX

ImmunityBio is a late-stage biotechnology company developing therapies and vaccines to fight cancer and infectious diseases by amplifying both natural killer cell and T cell responses. The company's lead immunotherapy candidate, Anktiva (N-803), is an IL-15 superagonist designed to activate the body's immune system. ImmunityBio has received FDA approval for Anktiva in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer and is evaluating it in multiple other cancer indications. The company also developed a COVID-19 vaccine and is advancing cell therapy programs through its subsidiary NantKwest.